NCT00089869已完成1 期
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 20
研究概览
简要总结
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have a clinical diagnosis of Schizophrenia
- •Must be at least 18 years of age and not older than 55 years of age
- •Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
- •Women of childbearing potential must be using a medically accepted means of contraception
- •Must be able to swallow capsules
排除标准
- •Has serious health problems other than Schizophrenia
- •Takes an antidepressant for depression
- •Takes insulin for diabetes
- •Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months
研究者
研究点 (20)
Loading locations...
相似试验
已完成
4 期
Abilify as an Adjunctive Treatment for Refractory DepressionDepressive Disorder, MajorNCT00220636St. Luke's-Roosevelt Hospital Center15
已完成
4 期
Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive DisorderMajor Depressive DisorderNCT01696617Seoul National University Hospital46
终止
4 期
A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of SchizophreniaSchizophreniaNCT01615185Kaohsiung Kai-Suan Psychiatric Hospital96
已完成
4 期
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18
已完成
4 期
Olanzapine vs. Low-dose Olanzapine Plus TrifluoperazineSchizophreniaNCT02704962Kaohsiung Kai-Suan Psychiatric Hospital94